Dysbiosis and Rebiosis of the Periodontal Microbiome

牙周微生物群的失调和再生

基本信息

  • 批准号:
    MR/P012175/2
  • 负责人:
  • 金额:
    $ 55.08万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2017
  • 资助国家:
    英国
  • 起止时间:
    2017 至 无数据
  • 项目状态:
    已结题

项目摘要

The human body supports the growth of a wide array of microbial communities in the gastro-intestinal and urogenital tracts and on the surface of the skin. Together, these communities of bacteria are referred to as the human microbiome. It is widely acknowledged that the human microbiome plays a significant role in human biology through its influence on human development, physiology, immunity and nutrition. Although the composition of the human microbiome has received considerable attention in recent years, the precise mechanisms whereby the microbial communities mediate disease and maintain health remain uncertain. However, recent studies have shown that several chronic diseases of the mouth and gastro-intestinal tract are associated with alterations to the composition of the entire microbiome. This is referred to as dysbiosis where there are major and harmful shifts in the relative abundancies of individual components of the microbiome compared to the abundancies found in health. Periodontal disease is an example of these conditions where dysbiosis of the normal microbiology takes place. This disease is one of the most common inflammatory diseases of humans leading to tooth loss in approximately 20% of the population and a significant cost to the NHS. It is also thought to be a risk factor for the development of other diseases including cardiovascular disease and type II diabetes. Current treatment methods involve thorough cleaning of the tooth surfaces below the gum margin, sometimes supplemented by antibiotic therapy. However, even with regular treatment episodes this is not always successful. There is, therefore, an urgent unmet clinical need to develop newer methods of both diagnosis, prevention and treatment of this condition. Given the current concerns about the development of resistance to antibiotics, newer treatments for periodontal disease should aim to avoid the use of these valuable agents for more acute and life threatening conditions. Attempts to study these processes in humans have had limited success to date - possibly because of the large variation in clinical disease in human populations and because of the need for longitudinal studies over a long time scale: disease in humans is a slowly progressive disease. We have shown in studies using mice that introduction of the human periodontal organism, Porphyromonas gingivalis, into the mouth causes dysbiosis of the oral microbiome and the development of periodontal disease. P. gingivalis causes these major shifts to the normal microbiology even though it is present in very low quantities. We therefore refer to this bacterium as a keystone pathogen able to manipulate the composition of the normal bacteria in the mouth even though it is present in low abundance. Similar keystone pathogens have now been described in other inflammatory diseases of humans. We have also shown that the P. gingivalis disease- associated microbiome is very stable and can be transferred into healthy recipient mice and cause disease. This system therefore provides an ideal experimental model to determine mechanisms of dysbiosis of the oral microbiome and how this may be reversed in order to restore health. Specifically, in this investigation, we aim: 1. To determine how a keystone pathogen - in this case P. gingivalis - causes microbial dysbiosis2. To establish what are the functional properties of a dysbiotic periodontal microbiome compared to the microbiome in health3. To determine which component(s) or properties of a normal symbiotic microbiome may be used to reverse dysbiosis and hence restore health in a diseased individualThe overall aim of these investigations is to form a basic understanding of the mechanisms of dysbiosis of the periodontal microbiome and its potential reversal to a symbiotic state (rebiosis). Through these experiments we aim to provide the basis for the development of novel approaches to the treatment and prevention of human disease.
人体支持胃肠道和泌尿生殖道以及皮肤表面的各种微生物群落的生长。这些细菌群落被称为人类微生物组。人们普遍认为,人体微生物组通过其对人类发育、生理、免疫和营养的影响在人类生物学中起着重要作用。尽管近年来人类微生物组的组成受到了相当大的关注,但微生物群落介导疾病和维持健康的确切机制仍然不确定。然而,最近的研究表明,口腔和胃肠道的几种慢性疾病与整个微生物组组成的改变有关。这被称为生态失调,其中与健康中发现的丰度相比,微生物组的单个组分的相对丰度存在重大且有害的变化。 牙周病是这些条件的一个例子,其中发生正常微生物学的生态失调。这种疾病是人类最常见的炎症性疾病之一,导致大约20%的人口牙齿脱落,并给NHS带来巨大的成本。它也被认为是发展其他疾病的危险因素,包括心血管疾病和II型糖尿病。目前的治疗方法包括彻底清洁牙龈边缘以下的牙齿表面,有时辅以抗生素治疗。然而,即使有定期治疗事件,这也并不总是成功的。因此,迫切需要开发诊断、预防和治疗这种病症的更新方法。鉴于目前对抗生素耐药性发展的担忧,牙周病的新治疗方法应旨在避免将这些有价值的药物用于更急性和危及生命的疾病。迄今为止,在人类中研究这些过程的尝试取得的成功有限-可能是因为人群中临床疾病的差异很大,并且需要在很长一段时间内进行纵向研究:人类疾病是一种缓慢进展的疾病。我们在使用小鼠的研究中表明,将人类牙周生物牙龈卟啉单胞菌引入口腔会导致口腔微生物组的生态失调和牙周病的发展。牙龈卟啉单胞菌导致这些主要转变为正常的微生物学,即使它以非常低的量存在。因此,我们将这种细菌称为关键病原体,它能够操纵口腔中正常细菌的组成,即使它的丰度很低。类似的关键病原体现在已经在人类的其他炎症性疾病中被描述。我们还表明,牙龈卟啉单胞菌疾病相关的微生物组非常稳定,可以转移到健康的受体小鼠中并引起疾病。因此,该系统提供了一个理想的实验模型,以确定口腔微生物组生态失调的机制,以及如何逆转这种机制以恢复健康。具体来说,在这项调查中,我们的目标是:1。为了确定关键病原体-在这种情况下牙龈卟啉单胞菌-如何导致微生物生态失调2。确定与健康微生物组相比,牙周微生物群的功能特性。为了确定正常共生微生物组的哪些组分或特性可用于逆转微生态失调,从而恢复患病个体的健康,这些研究的总体目标是对牙周微生物组的微生态失调机制及其向共生状态(再生)的潜在逆转形成基本理解。通过这些实验,我们的目标是为开发治疗和预防人类疾病的新方法提供基础。

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Molecular basis for avirulence of spontaneous variants of Porphyromonas gingivalis: Genomic analysis of strains W50, BE1 and BR1.
  • DOI:
    10.1111/omi.12373
  • 发表时间:
    2022-06
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Aduse-Opoku, Joseph;Joseph, Susan;Devine, Deirdre A.;Marsh, Philip D.;Curtis, Michael A.
  • 通讯作者:
    Curtis, Michael A.
DS_10.1177_0022034519898144 - Supplemental material for The P. gingivalis Autocitrullinome Is Not a Target for ACPA in Early Rheumatoid Arthritis
DS_10.1177_0022034519898144 - 牙龈卟啉单胞菌自身瓜氨酸组的补充材料不是早期类风湿性关节炎中 ACPA 的目标
  • DOI:
    10.25384/sage.11536026
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    0
  • 作者:
    E. Muñoz-Atienza
  • 通讯作者:
    E. Muñoz-Atienza
A 16S rRNA Gene and Draft Genome Database for the Murine Oral Bacterial Community.
  • DOI:
    10.1128/msystems.01222-20
  • 发表时间:
    2021-02-09
  • 期刊:
  • 影响因子:
    6.4
  • 作者:
    Joseph S;Aduse-Opoku J;Hashim A;Hanski E;Streich R;Knowles SCL;Pedersen AB;Wade WG;Curtis MA
  • 通讯作者:
    Curtis MA
The Relationship between Mucins and Ulcerative Colitis: A Systematic Review.
  • DOI:
    10.3390/jcm10091935
  • 发表时间:
    2021-04-30
  • 期刊:
  • 影响因子:
    3.9
  • 作者:
    Bankole E;Read E;Curtis MA;Neves JF;Garnett JA
  • 通讯作者:
    Garnett JA
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael Curtis其他文献

SIMILAR OUTCOMES WITH THE SUPREME™BIODEGRADABLE DRUG COATED CORONARY STENT SYSTEM IN ACUTE CORONARY SYNDROME AND CHRONIC CORONARY SYNDROMES: RESULTS OF THE PROSPECTIVE MULTICENTER RANDOMIZED CONTROLLED PIONEER III TRIAL
  • DOI:
    10.1016/s0735-1097(21)02570-5
  • 发表时间:
    2021-05-11
  • 期刊:
  • 影响因子:
  • 作者:
    Alexandra J. Lansky;Shigeru Saito;Michael Curtis;Dean Kereiakes;Andreas Baumbach;Barry Bertolet;James Zidar;Brent McLaurin;Nabil Dib;Pieter Smits;Victor Alfonso Jimenez Diaz;Angel Cequier;Sjoerd Hofma;Cody Pietras;Stephan Windecker;Martin Leon
  • 通讯作者:
    Martin Leon
S147 - Liver Disease Among People who Inject drugs: A Prospective Longitudinal Cohort Study Linked to Administrative Hospital Data
S147 - 注射毒品者中的肝病:一项与行政医院数据相关的前瞻性纵向队列研究
  • DOI:
    10.1016/j.drugalcdep.2024.111567
  • 发表时间:
    2025-02-01
  • 期刊:
  • 影响因子:
    3.600
  • 作者:
    Samantha Colledge-Frisby;Michael Curtis;Jessica Howell;Ericka Flores;Paul Dietze
  • 通讯作者:
    Paul Dietze
Phenotyping people with a history of injecting drug use within electronic medical records using an interactive machine learning approach
使用交互式机器学习方法对电子病历中具有注射毒品使用史的人进行表型分析
  • DOI:
    10.1038/s41746-024-01318-y
  • 发表时间:
    2024-11-30
  • 期刊:
  • 影响因子:
    15.100
  • 作者:
    Carol El-Hayek;Thi Nguyen;Margaret E. Hellard;Michael Curtis;Rachel Sacks-Davis;Htein Linn Aung;Jason Asselin;Douglas I. R. Boyle;Anna Wilkinson;Victoria Polkinghorne;Jane S. Hocking;Adam G. Dunn
  • 通讯作者:
    Adam G. Dunn
The associations of poor psychiatric well-being among incarcerated men with injecting drug use histories in Victoria, Australia
澳大利亚维多利亚州被监禁男性的精神健康状况不佳与注射吸毒史的关系
  • DOI:
  • 发表时间:
    2018
  • 期刊:
  • 影响因子:
    3.5
  • 作者:
    R. Cossar;M. Stoové;S. Kinner;P. Dietze;C. Aitken;Michael Curtis;Amy Kirwan;J. Ogloff
  • 通讯作者:
    J. Ogloff
Tricyclic aminopyrimidine histamine H<sub>4</sub> receptor antagonists
  • DOI:
    10.1016/j.bmcl.2011.08.014
  • 发表时间:
    2011-11-01
  • 期刊:
  • 影响因子:
  • 作者:
    Brad M. Savall;Laurent Gomez;Frank Chavez;Michael Curtis;Steven P. Meduna;Aaron Kearney;Paul Dunford;Jeffery Cowden;Robin L. Thurmond;Cheryl Grice;James P. Edwards
  • 通讯作者:
    James P. Edwards

Michael Curtis的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael Curtis', 18)}}的其他基金

Dysbiosis and Rebiosis of the Periodontal Microbiome
牙周微生物群的失调和再生
  • 批准号:
    MR/P012175/1
  • 财政年份:
    2017
  • 资助金额:
    $ 55.08万
  • 项目类别:
    Research Grant
Dysbiosis of the oral microbiome in periodontal disease: host gene and pathogen effects
牙周病中口腔微生物群的失调:宿主基因和病原体的影响
  • 批准号:
    MR/J011118/1
  • 财政年份:
    2012
  • 资助金额:
    $ 55.08万
  • 项目类别:
    Research Grant
Characterisation of the common steps in the glycosylation of Arg-gingipains and synthesis of LPS and APS of P.gingivalis
牙龈卟啉单胞菌精氨酸糖基化以及 LPS 和 APS 合成中常见步骤的表征
  • 批准号:
    G0501478/1
  • 财政年份:
    2006
  • 资助金额:
    $ 55.08万
  • 项目类别:
    Research Grant
SBIR Phase I: Creating New Learning Opportunities: Platform-Independent, Wireless, Task-Oriented Communities
SBIR 第一阶段:创造新的学习机会:平台独立、无线、面向任务的社区
  • 批准号:
    0441338
  • 财政年份:
    2005
  • 资助金额:
    $ 55.08万
  • 项目类别:
    Standard Grant

相似海外基金

Dysbiosis and Rebiosis of the Periodontal Microbiome
牙周微生物群的失调和再生
  • 批准号:
    MR/P012175/1
  • 财政年份:
    2017
  • 资助金额:
    $ 55.08万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了